Botanix Pharmaceuticals (ASX: BOT)
Botanix Pharmaceuticals (ASX: BOT) is a clinical stage medical dermatology company, which is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. www.botanixpharma.com
Botanix’s CBD-based product destroys superbug skin infections in another ‘world first’
In another “world first” this week, Botanix Pharmaceuticals (ASX: BOT) has revealed its antimicrobial cannabidiol (CBD)-based product...
Botanix study finds CBD has anti-inflammatory and immune modulating effects on skin disease
New results from a “world-first” study by Botanix Pharmaceuticals (ASX: BOT) has identified significant anti-inflammatory and immune...
Botanix Pharmaceuticals and University of Queensland to develop cannabidiol treatment for superbugs
Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) is moving ahead with developing its BTX 1801 pipeline product, a cannabidiol-based...
Botanix Pharmaceuticals fully funded to complete phase 2 atopic dermatitis trial
Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) has raised A$8 million through an oversubscribed placement to professional, institutional and...
Botanix Pharmaceuticals receives strong results amid growing dermatitis rates
Dermatology company Botanix Pharmaceuticals (ASX: BOT) has published successful results from its phase 1b patient study looking...
Botanix receives FDA go-ahead for progressive acne treatment
Dermatology company Botanix Pharmaceuticals (ASX: BOT) has received the green light from the US Food and Drug...
Botanix poised to kick-off new study with CBD-based atopic dermatitis treatment
Botanix Pharmaceuticals (ASX: BOT) has now enrolled all patients required to kick-off its phase 1b atopic dermatitis...
Botanix’s acne treatment outperforms current ‘leading’ topical products
Botanix Pharmaceuticals’ (ASX: BOT) synthetic cannabidiol-based BTX 1503 acne treatment has performed better than “leading” topically applied...
Botanix Pharma’s acne product effects antibiotic-resistant acne
Medical dermatology company Botanix Pharmaceuticals (ASX: BOT) revealed trials of its synthetic cannabidiol-based acne product BTX 1503...
First patients enrolled for Botanix Pharmaceuticals’ dermatitis trial
Botanix Pharmaceuticals (ASX: BOT) has enrolled its first patients for its phase 1b clinical trial into its proprietary...
Botanix Pharmaceuticals kicks-off atopic dermatitis trials
Botanix Pharmaceuticals (ASX: BOT) is full steam ahead with beginning its atopic dermatitis study in Australia after...